William Lis Sells 13,814 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) Director William Lis sold 13,814 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.67, for a total transaction of $492,745.38. Following the sale, the director now directly owns 35,106 shares of the company's stock, valued at approximately $1,252,231.02. This trade represents a 28.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Zai Lab Price Performance

ZLAB traded down $0.77 during mid-day trading on Thursday, hitting $36.19. The stock had a trading volume of 563,086 shares, compared to its average volume of 906,547. The stock's fifty day simple moving average is $33.35 and its 200-day simple moving average is $31.02. The firm has a market capitalization of $3.99 billion, a price-to-earnings ratio of -14.53 and a beta of 0.96. Zai Lab Limited Unsponsored ADR has a 1-year low of $16.01 and a 1-year high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.05. The company had revenue of $106.49 million for the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. As a group, research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zai Lab

Large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Zai Lab during the fourth quarter worth $29,000. Pictet Asset Management Holding SA bought a new stake in shares of Zai Lab during the fourth quarter worth $31,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Zai Lab during the first quarter worth $75,000. Advisors Preferred LLC bought a new stake in shares of Zai Lab during the first quarter worth $110,000. Finally, Barclays PLC increased its position in shares of Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company's stock worth $97,000 after acquiring an additional 2,856 shares in the last quarter. Institutional investors own 41.65% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th. JPMorgan Chase & Co. boosted their price target on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th. Bank of America reissued a "neutral" rating and set a $36.10 price target (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Finally, Scotiabank assumed coverage on shares of Zai Lab in a research note on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price target for the company.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.